Jardiance (empagliflozin; Boehringer Ingelheim and Lilly) The approval was based on data from the phase 3 EMPEROR-Preserved trial. The Food and Drug Administration (FDA) has approved Jardiance ® ...
Empagliflozin improves cardiovascular outcomes in patients with heart failure, patients with type 2 diabetes who are at high cardiovascular risk, and patients with chronic kidney disease. The safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback